Apiquis 5mg Tablet

Apiquis 5mg Tablet

Apiquis 5mg Tablet is a high-potency pharmacological intervention containing Apixaban (5mg), a highly selective, reversible, and direct inhibitor of factor Xa, specifically engineered for the clinical management of venous thromboembolism (VTE) and the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). Utilizing a unique “Direct-Acting Anticoagulant” (DOAC) delivery system, this medication works by inhibiting both free and clot-bound factor Xa, as well as prothrombinase activity. By modulating the terminal stage of the coagulation cascade and preventing the conversion of prothrombin to thrombin, Apiquis effectively neutralizes the triggers of intravascular thrombus formation. This targeted biochemical action provides a decisive therapeutic response by reducing the risk of systemic embolism and protecting the cardiovascular system from ischemic events without requiring routine international normalized ratio (INR) monitoring.

Key Features

• Specifically formulated to target the central catalyst of the coagulation cascade for precise clot prevention.
• Clinically recognized for its role in significantly reducing the risk of stroke and systemic embolism in atrial fibrillation patients.
• Specifically engineered to provide consistent therapeutic effects without the need for routine blood monitoring or dietary restrictions.
• Acts as a functional catalyst for safety, demonstrating a reduced risk of major intracranial bleeding compared to traditional anticoagulants.
• Formulated to reach peak plasma concentrations within 3 to 4 hours, ensuring prompt protection against thrombus formation.

Key Ingredients

• Apixaban (5mg)
• Lactose Anhydrous
• Microcrystalline Cellulose
• Croscarmellose Sodium
• Magnesium Stearate

Precautions

• Consult with a cardiologist or hematologist before use, especially if you have a history of renal impairment, hepatic dysfunction, or active pathological bleeding.
• Use with extreme caution as Apixaban increases the risk of hemorrhage; monitor for signs of internal bleeding such as unusual bruising, nosebleeds, or dark stools.
• Inform your surgeon or dentist that you are taking Apiquis before any scheduled procedure, as it may need to be temporarily discontinued to manage bleeding risks.
• Strictly avoid use with strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, ritonavir) or other anticoagulants like heparin and warfarin unless specifically directed.
• Use with caution in patients undergoing spinal puncture or epidural anesthesia due to the risk of spinal hematoma and subsequent paralysis.
• Not recommended for use during pregnancy or lactation due to the potential risk of maternal and fetal hemorrhage.

How to Use

• Swallow the tablet whole with a full glass of water. It may be taken with or without food.
• For optimal clinical results, take one Apiquis 5mg tablet twice daily (morning and evening) at approximately the same time every day.
• Do not skip doses or discontinue therapy abruptly without consulting your physician, as this significantly increases the risk of stroke or blood clots.
• For patients with swallowing difficulties, the tablet may be crushed and suspended in water or apple juice immediately before ingestion.
• If a dose is missed, take it as soon as you remember. Do not double the dosage to compensate for a missed one; simply resume the twice-daily schedule.
• Keep the tablets in their original packaging, stored in a cool, dry place (below 30°C) away from direct sunlight and humidity.

Legal Disclaimer: Apiquis 5mg Tablet is a prescription-only medication. Individual results vary based on the baseline cardiovascular health and the patient’s metabolic profile. This product is not intended for the treatment of patients with prosthetic heart valves. This information is for educational purposes and is not a substitute for professional medical consultation or a formal hematological assessment.